&w=3840&q=100)
Is your makeup safe? Govt may soon ban mercury-based cosmetics in India
Mercury in cosmetics: Why you should be concerned
Ever wondered what's really inside your favourite cosmetic products? You might want to take a closer look at the label—because the toxic metal mercury could be hiding in your eyeliner or skin cream. Mercury isn't just harmful to the skin; it's a health hazard that can seep into your bloodstream and cause long-term damage.
It can cause skin rashes, discolouration, thinning of the skin, and even permanent scarring. According to the Mint report, mercury-based products such as skin-lightening creams, anti-ageing solutions, and some eye makeup items are particularly risky. These often deliver quick, 'miracle' results that tempt consumers—especially the young—but the long-term effects can be deeply damaging.
What do the current rules say about mercury in makeup?
Currently, Indian regulations permit limited mercury use. According to Rule 39(5) of the Cosmetics Rules, 2020, cosmetics meant for the eye area may contain up to 70 parts per million (0.007 per cent) of mercury as a preservative. For all other cosmetics, mercury should not exceed 1 ppm.
However, the DCGI's subcommittee is advocating a stricter standard—a complete ban on the manufacture, import, and export of any cosmetic containing more than 1 ppm of mercury. This would bring India in line with the Minamata Convention, which seeks to eliminate mercury from consumer products globally.
Self-declaration, surprise tests planned for compliance
Cosmetic companies may soon be required to self-declare whether they use mercury. This will be followed by surprise lab tests and random sampling by regulators such as the Central Drugs Standard Control Organisation (CDSCO).
An official quoted by Mint said, 'The logical step is to require manufacturers to self-declare their use of mercury, propose alternative formulations, and give them a strict deadline for phasing out mercury.'
How cosmetic brands are reacting
Some companies have already stated their position. L'Oréal India told Mint it does not intentionally use mercury in any of its products worldwide, and that its offerings meet the highest safety standards. Other leading brands such as Lakmé, Maybelline, Sugar Cosmetics, and Nykaa did not respond to media queries.
A government official noted, 'Wherever there is a casual approach in handling toxic substances, the risk to human life and the environment is high. The smarter path is to either properly manage toxic substances or stop using them entirely.'
Minamata Convention also targets mercury in household items
The Mint report noted that mercury-based household products—including certain medical devices—have been flagged for phase-out under the Minamata Convention. This global agreement aims to reduce human and environmental exposure to mercury.
What can consumers do to protect themselves?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Bigger fonts, clearer tags: How the drug regulator is looking to redesign hard-to-read medicine labels
New Delhi: Ever squinted at a medicine strip trying to find the expiry date, or popped a pill without knowing whether it's branded or generic? You're not alone. India's top drug regulator is stepping in to change that. The Drug Controller General of India (DCGI) is working on a nationwide overhaul of medicine packaging and labelling norms. The goal is to make expiry dates and batch numbers easier to read, reduce confusion between generic and branded drugs, and help patients, make better-informed choices, two government officials aware of the matter said. As part of the proposed changes, manufacturers may soon be required to use larger fonts, ditch shiny packaging that reflects light and obscures print, and print expiry dates in more than one place to prevent vital information from being torn off. There's also a plan to introduce a universal symbol to clearly distinguish generic medicines from branded ones. The regulator had received several complaints regarding the difficulty in differentiating between cheaper generic drugs and their branded counterparts, and consequently, the pricing comparison. "The drug regulator has received various complaints and demands from the consumers regarding the labelling of medicinal products such as tiny font size of the letters printed on the drug packaging, shiny labels, the expiry date of the medicines getting torn while taking out the medicine, and demand for universally recognised symbol on the generic medicines that will distinguish it from the branded medicines," said one of the officials cited above requesting anonymity. A sub-committee, set up by the DCGI, is reviewing the proposals and is expected to submit its report soon, the second official said. The committee is also examining ways to incorporate these changes under the Drugs and Cosmetics Rules, 1945, which governs the quality of drugs manufactured, imported, and sold in the country. Queries sent to the health ministry on Monday and DCGI spokesperson on Tuesday remained unanswered till press time. Also Read: India's drug regulator plans overhaul of Schedule H for prescription medicines Branded vs generic While both generic and branded medicines contain the same active ingredient and are expected to have the same therapeutic effect, their key differences lie in cost, brand recognition, and patent status. Branded medicines such as a well-known painkiller, often carry a higher price tag due to the research, development, and extensive marketing by the innovator company. Generic medicines, on the other hand, are typically much cheaper (often 80-85% less) because they are manufactured after the original drug's patent expires, eliminating the need for costly R&D and marketing. For instance, if 'PainRelief Pro' is a popular branded drug for headaches, its generic equivalent, say 'Paracetamol 500mg', will offer the same relief at a fraction of the cost. But customers often miss this. They ask for affordable, quality medicines but are often unaware of generic alternatives, said Rajiv Singhal, president and General Secretary of the All India Organization of Chemists and Druggists (AIOCD) representing 1.2 million members in the country. He called for expiry and batch details to be printed in clearer, larger fonts in multiple places to prevent accidental torn off. 'If this regulation comes into play, companies will have to mandatorily follow," he said, emphasizing the importance of regulatory enforcement. The development assumes significance given that India holds the distinction of being the world's largest supplier of generic drugs, accounting for approximately 20% of the global supply and manufacturing around 60,000 generic brands across 60 therapeutic categories. Mint had earlier reported that DCGI was considering Braille labelling on drug packaging to support the 4.95 million blind and 70 million visually impaired people in India. Global standards Globally, drug labels tend to be much simpler. Dr. Viranchi Shah, national spokesperson for the Indian Drugs Manufacturers Association (IDMA), said Indian medicine strips are detailed compared to their international counterparts. For example, international labels often only state the tablet's name, omitting details like coating information or the explicit phrase "to be sold on the prescription of registered medical practitioners." Instead, the "Rx" symbol is commonly used to indicate a prescription requirement, with its absence signifying an over-the-counter (OTC) drug. The extensive information and specific font size requirements on Indian labels are seen as cumbersome, leading to substantial inventory costs and a significant financial burden on companies for redesigning packaging, Shah said. He said that the industry is open to changes for the greater good and informed that IDMA had previously submitted its representation to the DCGI years ago, suggesting simplified labelling. He said that a key hurdle to such changes is the significant inventory held by pharmaceutical companies. Changes to labelling would require a phased approach to avoid disruption. 'Any future changes, whenever and however implemented, should consider suggestions from both patients and the industry, and be introduced in a phased manner to minimize disruption." This step will empower patients and enhance transparency in the Indian pharmaceutical market, said Nikkhil K. Masurkar, CEO, Entod Pharmaceuticals. The current lack of visual cues on packaging, he said, often leaves patients unaware of generic alternatives. The government's Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) may also benefit from the labelling overhaul. PMBJP operates over 17,000 Janaushadhi Kendras across India to offer quality generic medicines at affordable rates. Also Read: Centre orders thorough safety review of painkiller Nimesulide for adults India's pharmaceutical market, meanwhile, continues to expand. According to Pharmarack, the Indian Pharmaceutical Market (IPM) reached ₹19,720 crore in sales for May 2025, showing a 7.2% YoY growth. On a moving annual total (MAT) basis, the industry posted ₹2.29 trillion, reflecting an 8.1% annual growth and 9.8% CAGR. While pharma companies may face some logistical costs in updating their packaging, the industry believes these are manageable and worth the impact on patient safety, affordability, and transparency.
The Print
5 hours ago
- The Print
Delhi HC asks DGCI to decide representation over weight-loss drugs
A plea filed by Jitendra Chouksey said licenses issued for the use and sale of such drugs were not based on adequate data. A bench of Chief Justice D K Upadhyaya and Justice Tushar Rao Gedela asked the petitioner to give a representation to the DGCI, which was asked to decide the matter within three months. New Delhi, Jul 2 (PTI) The Delhi High Court on Wednesday asked the Drug Controller General of India to consult experts and relevant stakeholders in deciding a plea over drug combinations sold in the market for weight loss treatment. In an apparent reference to the recent death of popular TV actor Shefali Jariwala, the court said, 'See what happened two-three days back…' News reports suggest Jariwala was taking anti-ageing treatment for the last several years. The petitioner claimed the licenses have been issued without conducting any specific trials and studies and without noting the serious adverse health effects of the drugs. 'These drugs were originally developed and internationally approved for the treatment of Type 2 Diabetes Mellitus, with their primary therapeutic role being the regulation of glycemic levels. However, over the past few years, they have been repurposed and approved often through accelerated pathways for obesity treatment and chronic weight management, based largely on short-term efficacy trials,' the plea said. It said under the Drugs and Cosmetics Act, it is the DCGI which is the competent and statutory authority entrusted with taking appropriate measures to ensure safe use of drugs. The petitioner said representations were made on April 18 to the Centre and DCGI on the issue. The court, however, said the plea's concerns have to be first looked into and addressed by the DCGI as it allowed the petitioner to move the authority by way of an additional representation and bring relevant material and documents to its notice. The additional representation was directed to be submitted to the DGCI within a fortnight. 'In case such an additional representation is preferred enclosing all the documents and material necessary for addressing the issue raised in the writ petition, the same shall be attended to and considered appropriately and as per law by the authority concerned,' the court said. The order added, 'DCGI shall consult experts as also other stakeholders such as manufacturers of the drugs in question.' PTI SKV SKV AMK AMK This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
The Hindu
6 hours ago
- The Hindu
Air pollution is a greater threat than tobacco, says doctor
Former director of All India Institute of Medical Sciences-Delhi and renowned pulmonologist Randeep Guleria issued a stark warning about the public health crisis posed by air pollution, calling it a greater threat than tobacco, during an address in Hyderabad on Tuesday, celebrated as National Doctors' Day. Speaking at the event organised by the Indian Medical Association, Dr. Guleria urged the medical community to adopt the 'One Health' approach that integrates human, animal and environmental health. 'Air pollution is a silent killer,' Dr. Guleria said, citing recent studies that attribute 8.1 million deaths globally in 2021 to air pollution, a toll greater than that of COVID-19. He said the rise of non-communicable diseases such as cancer, diabetes, and cardiovascular disorders has overtaken communicable diseases as the dominant health burden in India, particularly in southern States. 'Air pollution is now among the top three causes of death and disability globally, and we are not paying enough attention,' he said. Highlighting how particulate matter smaller than 2.5 micrometres can penetrate deep into the lungs and bloodstream, Dr. Guleria explained its link to a range of diseases, including asthma, strokes, dementia, low birth weight, and even osteoporosis in postmenopausal women. 'We now have evidence that air pollution is linked to type 1 and type 2 diabetes, reproductive issues and even spontaneous abortions,' he said. He also drew attention to the disproportionate impact of poor air quality in Indian cities. He referred to a recent study covering ten Indian cities, including Hyderabad, Mumbai, Varanasi and Shimla, that showed a 1.4% rise in daily mortality associated with PM2.5 exposure, even at pollution levels below India's current permissible standards. 'This is not a Delhi problem. It is a Hyderabad problem, a Varanasi problem, a Srinagar problem. The entire nation is breathing poison,' he said. He also warned that current Indian air quality standards are far above what the World Health Organization recommends, and called for urgent revision and implementation. 'Pandemics are not rare anymore. In the last 25 years, we have seen two global pandemics and several major outbreaks. This is directly tied to how we are treating the planet,' he said. He concluded with a call for collaborative, multi-sectoral action. 'We need doctors, veterinarians, environmental scientists, urban planners, and policy-makers to work together. Without a unified approach, we will keep losing lives, silently and steadily to the air we breathe and the systems we ignore.' The event was attended by Indian Medical Association (IMA) national president Dilip Bhanushali, IMA Telangana president Dwarkanath Reddy and AIG Hospital chairman D. Nageshwar Reddy among other senior doctors.
